Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising brain cancer vaccine made available to patients with no other options

NCT ID NCT04802447

First seen Sep 30, 2025 · Last updated May 20, 2026 · Updated 33 times

Summary

This program gives certain glioblastoma patients at Roswell Park access to SurVaxM, a treatment that may help slow tumor growth and extend survival. It is for patients who have no other treatment options or who have already benefited from SurVaxM in a prior study. The goal is to provide continued care while monitoring safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

Explore the condition pages connected to this study.